tbuckley/cabot-search huggingface dataset:
FRI0572 Social and Emotional Impact of Rheumatic Diseases in Patients Treated with Subcutaneous Biological Therapy. Rheu Life Survey:
Authors: E. Batlle, C.M. González, L. Carmona, A.I. Torralba Gόmez-Portillo, L. Cea-Calvo, M.J. Arteaga, F.J. de Toro
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatic diseases impair patients9 everyday life but this is rarely assessed in clinical studies. <h3>Objectives</h3> To describe the social and emotional impact perceived, as a consequence of the disease, by patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) treated with biological drugs. <h3>Methods</h3> RHEU-LIFE was a survey to patients with RA, axial SpA and PsA from Spain. Rheumatologists from 50 outpatient hospital clinics handed the survey to 20 consecutive patients &gt;18 years-old who attended the clinic, they completed the survey at home and returned by pre-paid post mail. Patients were surveyed on the perceived impact of their rheumatic disease on five areas: 1) quality of life in general; 2) emotional state; 3) work or daily activity; 4) personal relations and 5) life of their families, responding with the options "no impact", "some", "moderate" or "severe". <h3>Results</h3> The survey was given to 1000 patients; 592 responded (response rate 59.2%, mean age 51.7 years [SD 13.2], 42.4% men and 57.6% women). Patients9 disease were RA (n=304, 54.2%), axial SpA (n=141, 25.1%) and PsA (n=116, 20.7%). 31 patients did not identify their disease. The percentage of patients who considered that the disease moderately or severely affected the different areas is shown in the table. A higher percentage of women vs men declared that the disease moderately or greatly affected all the areas (table). Similarly, aged patients described a greater impact than those who were younger (table). No differences were observed with regard to the disease, with similar percentages of patients with RA, axial SpA or PSA declaring "moderate" or "severe" impact in all areas (all, p&gt;0.1). <h3>Conclusions</h3> Patients with RA, axial SpA and PsA treated with biological drugs describe a significant impact in their quality of life, work or daily activity, emotional state, personal relations and life of their families, especially women and elderly patients. The impact was ranked similarly regarding the baseline disease. <h3>Acknowledgement</h3> This survey was financed by Merck Sharp &amp; Dohme of Spain and endorsed by the patients9 association ConArtritis (Arthritis National Coordinator). <h3>Disclosure of Interest</h3> None declared
The Uptake of Recombinant Glucocerebrosidases by Blood Monocytes From Type 1 Gaucher Disease Patients Is Heterogeneous
Authors: Juliette Berger, Jérome Stirnemann, Céline Bourgne, Bruno Pereira, Pascale Pigeon, Djazia Heraoui, Chantal Rapatel, Christian Rose, Nadia Belmatoug, Marc G Berger
Journal: Blood (2011)
Multivariate Analysis of Prognostic Factors in CLL: A Study on 431 Patients Showing Usefulness of Novel Biological and Old Clinical Parameters in Predicting Shorter Survival: An Italian Multicentric Study
Authors: Luca Laurenti, Michela Tarnani, Pietro Bulian, Gianluca Gaidano, Davide Rossi, Francesco Forconi, Silvia Deaglio, Francesco Bertoni, Dimitar G Efremov, Roberto Marasca, Giovanni Del Poeta, Fabio Malavasi, Valter Gattei
Journal: Blood (2008)
Fusion to Vp16 Converts MEIS1 into an Oncoprotein That Immortalizes Progenitors and Causes AML in the Absence of Coexpressed Hox Genes: Hoxa7 and Hoxa9 Induced Further Stem Cell Gene Transcription in Vp16MEIS1 Progenitors.
Authors: Gang G. Wang, Martina P. Pasillas, Mark P. Kamps
Journal: Blood (2005)
A TSLP-complement axis mediates neutrophil killing of methicillin-resistant <i>Staphylococcus aureus</i>
Authors: Erin E. West, Rosanne Spolski, Majid Kazemian, Zu Xi Yu, Claudia Kemper, Warren J. Leonard
Journal: Science Immunology (2016)

Community-acquired Staphylococcus aureus infections often present as serious skin infections in otherwise healthy individuals and have become a worldwide epidemic problem fueled by the emergence of strains with antibiotic resistance, such as methicillin-resistant S. aureus (MRSA). The cytokine thymic stromal lymphopoietin (TSLP) is highly expressed in the skin and in other barrier surfaces and plays a deleterious role by promoting T helper cell type 2 (TH2) responses during allergic diseases; however, its role in host defense against bacterial infections has not been well elucidated. We describe a previously unrecognized non-TH2 role for TSLP in enhancing neutrophil killing of MRSA during an in vivo skin infection. Specifically, we demonstrate that TSLP acts directly on both mouse and human neutrophils to augment control of MRSA. Additionally, we show that TSLP also enhances killing of Streptococcus pyogenes, another clinically important cause of human skin infections. Unexpectedly, TSLP mechanistically mediates its antibacterial effect by directly engaging the complement C5 system to modulate production of reactive oxygen species by neutrophils. Thus, TSLP increases MRSA killing in a neutrophil- and complement-dependent manner, revealing a key connection between TSLP and the innate complement system, with potentially important therapeutic implications for control of MRSA infection.
Patterned SLIPS for the Formation of Arrays of Biofilm Microclusters with Defined Geometries
Authors: Julia Bruchmann, Ivana Pini, Tejeshwar S. Gill, Thomas Schwartz, Pavel A. Levkin
Journal: Advanced Healthcare Materials (2016)

Biofilms represent an immense problem in medicine due to their strong drug-resistant properties and inherent stress-response activities. Due to the inhomogeneous and very complex architectures of large biofilm aggregates, biofilm studies often suffer from low reproducibility. In this study, an approach to form arrays of homogeneous biofilm microclusters with defined 2D geometries is presented. The method is based on the formation of water-infused hydrophilic porous polymer areas with precise geometries separated by "slippery" lubricant-infused porous surface (SLIPS). Due to the SLIPS' biofilm repellent properties, multiple identical 3D biofilm clusters are formed in the hydrophilic patches that can be used for biofilm screening. Formation of biofilm microcluster arrays of different bacterial strains of Pseudomonas aeruginosa on the SLIPS micropatterns is investigated. Critical parameters influencing minimal adhesive regions for biofilm attachment and minimal SLIPS dimensions to avoid biofilm adhesion are studied. The ability to produce arrays of biofilm microclusters with highly uniform, well-defined shapes opens an opportunity to study interactions of biofilms with various medically relevant factors with a better reproducibility and to investigate the complex biofilm architecture, heterogeneity, and interactions between biofilm subpopulations.
AB0150 Understanding The Role of The IL12/iL35 Balance in Sjögren Syndrome
Authors: O. Fogel, E. Rivière, R. Seror, G. Nocturne, B. Ly, S. Boudaoud, J.-E. Gottenberg, J.-J. Dubost, V. Le Guern, P. Dieudé, P. Chanson, J. Nititham, K. Taylor, L. Criswell, X. Mariette, C. Miceli-Richard
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren Syndrome (pSS) is an autoimmune disease mediated by B-cells as evidenced by the occurrence of non-Hodgkin lymphoma mainly involving salivary glands and increased B-cell activation markers in the serum of pSS patients. A type I interferon response is also observed among some patients. However, some mice models and large genetic studies suggest an alternative/coexisting involvement of the Th1 pathway in the pathophysiology of the disease. In fact, polymorphisms of <i>IL-12A</i>, which encodes for IL-12p35, have been associated with pSS<sup>1</sup>. IL-12p35 subunit is shared by 2 heterodimers, IL-12 and IL-35. <h3>Objectives</h3> To confirm the genetic association of <i>IL-12A</i> polymorphism with pSS and to elucidate the involvement of the IL-12/IL-35 balance in pSS through functional studies. <h3>Methods</h3> The genetic studies were performed on French pSS from 2 cohorts. Functional studies were performed on sorted monocytes and stimulated <i>ex vivo</i> under inflammatory conditions. Interleukin-12A mRNA, IL-12 and IL-35 proteins were quantified by qRT-PCR for mRNA and by ELISA and multiplex kit respectively for IL-35 and IL-12. <h3>Results</h3> We confirmed the association between rs485497 and pSS and found an increased level of IL-12 in sera of pSS patients carrying the risk allele (p=0.016). IL-12 was increased in pSS compared to healthy controls (p=0.0001), especially in patients with a more active disease contrary to IL-35 which was decreased in pSS (p=0.0001). We observed that 99% of patients with high serum levels of IL-35 did not developed lymphoma <i>versus</i> 93% in the group with low IL-35 (p=0.03). <h3>Conclusions</h3> Our findings emphasize the involvement of the balance IL-12/IL-35 in the pathogenesis of pSS. Further studies especially on regulatory B-cells and plasma cells as well as in animal models of autoimmune diseases assessing the effect of recombinant IL-35, would help to decipher whether this regulatory cytokine could be of interest for future therapeutic approaches. <h3>References</h3> Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren9s syndrome. Nat Genet. nov 2013;45(11):1284–92 <h3>Acknowledgement</h3> Année recherche ARS Midi-pyrenées <h3>Disclosure of Interest</h3> None declared
PTH-125 BSG VS UEG – Which Annual Meeting has The Highest Conversion Rate of Abstracts to Full Publication?
Authors: M Kurien, AD Hopper, R Akram, R Glover, A Issa, E Peever, J Purves, E Scanu, DS Sanders
Journal: Gut (2016)

<h3>Introduction</h3> Abstract presentations at scientific meetings allow rapid dissemination of novel research and enables peer review before submission for publication. The percentage of abstracts that achieve full publication, however is variable ranging between 11–78% from other medical specialty meetings. This study evaluates the conversion rate of abstracts presented at the BSG annual meeting, and comperes the outcome from this national meeting with another internationally recognised gastrointestinal meeting (UEGW). <h3>Methods</h3> All abstracts presented at the BSG between 1994 and 2008 were reviewed in Nov 2012. UEGW meeting abstracts between 2009 and 2011 were reviewed in October 2014. Review dates for both the BSG and UEGW abstracts were at least 3 years post the last meeting evaluated, which is a previously reported upper limit timescale for subsequent full publication. PUBMED and EMBASE databases were reviewed using cross-referencing of first author, senior author and at least one key word from the abstract title. Abstracts and possible full publications were then examined in tandem to ensure they represented the same study. Abstracts that were withdrawn were excluded from the study. In addition to publication rates, data was collected on lag time to publication and journal impact factors. Statistical analyses were performed using contingency tables and chi squared statistics for categorical data using SPSS version 20.0. <h3>Results</h3> Over a 15 year period (1994–2008) the conversion rate of BSG abstracts to full publication was 33.4% (2273/6798, mean impact factor of published journal = 3.8). The mean lag time until publication was 23 months, with service development abstracts having the lowest conversion rate of 6.9% (8/116). Of the 6560 abstracts presented at UEGW meetings between 2009–2011, 31.0% (2033/6560) went on to full publication in indexed journals (mean impact factor = 3.93). The mean lag time between UEG abstract presentation and full publication was 16 months. The conversion rate of BSG abstracts is broadly comparable to UEGW, however it did achieve a statistically significant difference (33.4% vs.31.0% p = 0.003). <h3>Conclusion</h3> This study demonstrates that the BSG compares favourably to another internationally recognised gastroenterology meeting with regards to the outcomes of its abstracts. Findings from this work provides reassurances to researchers that submission to the BSG annual meeting is worthwhile, and that the peer-review process provided increases the likelihood of success in achieving subsequent full publication. <h3>Disclosure of Interest</h3> None Declared
AB0777 Bone Metabolism and Osteoporosis Risk Factors Analysis in Spinal Cord Injury Patients:
Authors: E. Grau Garcia, I. Martínez Cordellat, J. Valero Sanz, F. Torralba Collados, C. Grao Castellote, J. Ivorra Cortés, L. González Puig, I. Chalmeta Verdejo, C. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuan, K. Arévalo Ruales, R. Negueroles Albuixech, J. Fragio Gil, C. Alcañiz Escandell, G. Poveda Marín, C. Nájera Herranz, V. Fornes Ferrer, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is noticed that spinal cord injury (SPI) is a difficult process associated to patient immobilization which leads to bone mass decrease, osteoporosis risk and high risk of bone fracture. In these patients a low bone mass and bone resorption is observed, even in the six months after SPI, and this situation stabilizes over the next 22–26 months after injury. Moreover there is an increased bone fracture risk due to the high risk of osteoporosis. <h3>Objectives</h3> To assess bone metabolism and bone fracture incidence in SPI patients. <h3>Methods</h3> Prospective study of SPI patients from the Spinal Cord Injury Unit of La Fe Hospital. In all cases lower backs and hips densitometry, spinal cord plain x-ray image, bone metabolism biomarkers and clinical evaluation have been performed. Statistical techniques was carried out using R software 3.2.3. <h3>Results</h3> We studied 37 patients with SCI, 46% of them women, with a mean age at SPI of 54.38±24.77 years. The 58.9% of patients showed thoracic injuries, 48.6% paraparesis and 46.7% presented level C in Asia scale. Results from biochemical markers of bone turnover and densitometry are showed in the table. We observed a statistically association between decreased vitamin D values and increased values of bCTX (P=0.002) and PTH (P=0.03). In addition, altered PTH and vit D values are associated with thoracic location of the SCI (P=0.03), total loss of mobility (P=0.02) and high levels in Asia Scale (P=0.004). Also, classic osteoporosis risk factors were evaluated, and they were significantly and inversely related to alcohol consumption (P=0,022), frequent falls in the last year (P=0.02), long-term use of anticoagulants (P=0.006), and altered values of PTH and vitamin D. <h3>Conclusions</h3> A high proportion of our SCI patients showed serum vitamin D deficit, associated to high levels of bCTX and PTH. Moreover, patients with the lowest vitamin D levels were more likely to have higher limitation of movement and higher Asia Scale levels. <h3>Disclosure of Interest</h3> None declared
FRI0089 C4M – A Blood-Based Biomarker – Is An Objective Marker of Disease Activity and Radiographic Status: Replication and Validation or Previous Findings in The Oskira Rheumatoid Arthritis Studies
Authors: N.S. Gudmann, A. Platt, M. Karsdal, A.C. Bay-Jensen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is an inflammatory joint disease affecting multiples tissues including the soft connective tissue surrounding the joints as well as the cardiovascular system. C4M is a biomarker of type IV collagen degradation, which is solely released from the basement membrane of, for example, the vasculature system. C4M was tested in the phase III clinical trial LITHE and was found to be a biomarker of disease activity and radiographic burden. <h3>Objectives</h3> The aim of this study was to replicate and validate previous findings of C4M by measuring patient samples from the OSKIRA phase III clinical trials. <h3>Methods</h3> OSKIRA 1, 2 and 3 (NCT01197521; NCT01197534; NCT01197755) (n=543) were all phase 3, randomized, double-blind, placebo-controlled studies of fostamatinib on a MTX background including RA patients with moderate to severe disease. Only baseline serum samples from the placebo arms were assessed. Patient population differed between the studies in that patients had inadequate response to: MTX (OSKIRA 1), DMARDs (OSKIRA 2) and single anti-TNF-α treatment (OSKIRA 3). Disease activity was assessed by disease activity score 28 (DAS28), swollen joint count 28 (SJC28), tender joint count 28 (TJC28) and health assessment questionnaire (HAQ). Radiographic Status was evaluated by joint space narrowing (JSN), erosion score (ERN) and mTSS. Serum C4M was measured in fasting serum by solid-phase competitive ELISA. Spearman rank correlations were applied to investigate the association between C4M and clinical parameters. Independent t-tests were applied for intergroup comparisons. Data that did not meet the criteria of normal distribution were log transformed prior to t-tests. <h3>Results</h3> Demographics were comparable for the three OSKIRA studies and the placebo groups of each were therefore pooled together. Baseline levels of C4M were significantly correlated with the disease activity parameters DAS28 (r=0.377, p=0.0001), HAQ (r=0.206, p&lt;0.0001), TJC28 (r=0.117, p=0.0068) and SJC28 (r=0.166, p=0.0001) and radiographic scores: ERN (r=0.135, p=0.003), mTSS (0.151, p=0.001) and JSN (r=0.152, p=0.001). There were no significant correlations between C4M and sex, age or BMI. There were no significant differences in C4M2 measurements in escapers versus non escapers or at baseline compared to the concentrations measured at week 24. <h3>Conclusions</h3> The OSKIRA studies support previous findings of the LITHE study. C4M is highly associated with disease activity as well as radiographic progression level in patients with RA. Basement membrane remodelling, measured by C4M, appears to be highly important to the pathogenesis of RA. Further studies may reveal if alterations in basement membrane are linked to vascular dysfunction in patients with RA. <h3>Disclosure of Interest</h3> None declared
Alteration of Circulating Regulatory T Cells in Japanese Adult Patients with Immune Thrombocytopenic Purpura after Eradication of Helicobacter Pylori.
Authors: Koji Miyazaki, Mikio Danbara, Manabu Ohsaka, Yuhko Suzuki, Ryouichi Horie, Masaaki Higashihara
Journal: Blood (2008)
Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.
Authors: Steven P. Treon, Jacob D. Soumerai, Christopher J. Patterson, Zachary R. Hunter, Irene M. Ghobrial, Rose Villarreal, Michael A. Willen, Thomas J. Myers
Journal: Blood (2006)
PTU-071 The Long Term Safety and Efficacy of Co-Therapy Allopurinol with Low Dose Azathioprine or Mercaptopurine Without Metabolic Profiling in Inflammatory Bowel Disease
Authors: P Pavlidis, P Stamoulos, A Taylor Gonzalez, R Reynolds, C Bull, K Street, A Ansari
Journal: Gut (2016)

<h3>Introduction</h3> The effectiveness of full dose azathioprine (FDA) for inflammatory bowel disease (IBD) is increasingly recognised as poor and often requires the use of anti-TNF therapies. Current strategies to optimise azathioprine (AZA) includes the use low dose azathioprine with allopurinol (LDAA). However, many groups restrict LDAA to patients classed as shunters/hypermethylators (15% of non-responders) based on thiopurine metabolite (TM) assay profiles. This approach inadvertently denies i) 85% of non-responders ii) those without access to TM iii) those with poor understanding of these complex recommendations to benefit from LDAA. <h3>Methods</h3> Records of IBD patients treated with LDAA were retrospectively analysed. AZA dose was reduced to 25–33% of the thiopurine methyl transferase (TPMT) adjusted dose. The response was determined after 6 months and assessed for steroid free clinical remission. A cohort of patients had thiopurine metabolite measurements: i) Non Response (NR) to FDA (n 30) then repeated on LDAA (n 20). ii) Further 70 on LDAA NR (n 20) and full response (FR) (n 50). <h3>Results</h3> Four hundred patients received LDAA between 2009 and August 2015. Group 1 (G1)- 1<sup>st</sup> line (n190); Group 2 (G2)-switched from FDA to LDAA (n210). Overall 280 (70%) had a FR (G1 and G2), the rest non-responders (NR): In G1 FR was 79% and G2 65%. Myelotoxicity occurred in 8 patients; 8 patients on LDAA had hepatotoxicity which resolved by increasing allopurinol to 200 mg (all FR). The median length of therapy was 38 months. Metabolites: i) For FDA: 20 complete responders (TGN mean 280) and 30 non responders (TGN mean 260): 6 non adherent (TGN &lt; 150 and low MMP) and 4 shunters tendency (MMP &gt; 5,000 and low TGN). In 20 switched to LDAA (TGN mean for Complete Response 420 and Non Response 440). ii) In Complete Response to LDAA (TGN mean 476), and FDA (TGNs mean 306). In LDAA Non Response (TGN mean 400). Analysis: Mann-Whitney test. For commercial RBC TGNs: CR vs NR in FDA and LDAA p-value = 0.3132 and 0.9386 respectively. The TGNs increased significantly in both CR and NR switched from FDA to LDAA (p &lt; 0.05). <h3>Conclusion</h3> Appropriately dosed LDAA therapy is therapeutically effective, well tolerated and relatively safe compared to FDA. Giving LDAA to patients who are not shunters does not diminish the benefit of LDAA. Avoiding metabolite determined use of LDAA increases the number of patients who can benefit from AZA. The observed Increase in TGNs seen in patients switched to LDAA occurs in both NR and CR. <h3>Disclosure of Interest</h3> None Declared